Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study

Exclusion Criteria

• •Patients who can benefit from curative treatment (surgical resection, liver transplant or treatment via percutaneous destruction)
• •Non-cirrhotic liver
• •Cirrhosis Child B8 or B9 or C
• •Extrahepatic metastases (pulmonary micronodules \< 7mm are not considered a contra-indication)
• •Digestive hemorrhage within the previous month
• •Patient on anticoagulants
• •Pregnant women
• •Uncontrolled infection
• •Hypersensitivity to anthracyclines
• •Hypersensitivity to iodine contrast agents
• •Patient under guardianship or ward of court
• •Patients who have already received the recommended cumulative dose of anthracycline (93 mg/m2 for idarubicin, 140 mg/m2 for mitoxantrone, 550 mg/m2 for doxorubicin, 600 mg/m2 for daunorubicin, 900 mg/m2 for epirubicin)